|
| Guidelines for the Management of Heavy Menstrual Bleeding |
| On September 30, 2004, Vioxx (rofecoxib) was withdrawn from the U.S. and worldwide market due to safety concerns of an increased risk of cardiovascular events. See the U.S. Food and Drug Administration (FDA) Web site for more information. Subsequently, on December 23, 2004, the FDA issued a public health advisory concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs) including the COX-2 selective agents Celebrex (celecoxib), Bextra (valdecoxib) and a non-selective NSAID, naproxen (sold as Aleve, Naprosyn and other trade name and generic products). See the FDA web site for more information . |
Send us your comments
Note: All fields are required.
This guideline has been produced by National Health Committee (NHC). Responses may take longer to process as we will need to consult with the organisation before replying. |
|
|
| « Back |
If you would like further information about this guideline, please contact the relevant organisation directly. Contact details are located in the 'Produced By' area on the homepage of this template. Please note that hard copies may no longer be available.
|
|
